Nuvectis Pharma | Investor Presentation Deck | 23 slides — playbook

Nuvectis Pharma | Investor Presentation Deck | 23 slides

Nuvectis Pharma · 2023-08

arc beats above · slides in the middle · loops below · scroll → 2 LOOPS

Deck intelligence map

5

coverage by narrative range · generated from this deck JSON

Narrative range 28 total

Metadata

Components

Metrics

Tools

Frameworks

Beats

Loops

Problem 1 slides 100% 1/1 slides 100% 1/1 slides · 2 hits

— 0/1 slides

— 0/1 slides

— 0/1 slides

100% 1/1 slides 100% 1/1 slides Solution 14 slides 100% 14/14 slides 100% 14/14 slides · 75 hits

— 0/14 slides

50% 7/14 slides · 8 hits 28.6% 4/14 slides 100% 14/14 slides · 26 hits 100% 14/14 slides · 28 hits Traction 3 slides 100% 3/3 slides 100% 3/3 slides · 19 hits

— 0/3 slides

— 0/3 slides

— 0/3 slides

100% 3/3 slides · 6 hits 100% 3/3 slides · 6 hits Roadmap 9 slides 100% 9/9 slides 100% 9/9 slides · 43 hits

— 0/9 slides

66.7% 6/9 slides · 7 hits 33.3% 3/9 slides 100% 9/9 slides · 18 hits 100% 9/9 slides · 18 hits Team 1 slides 100% 1/1 slides 100% 1/1 slides · 6 hits

— 0/1 slides

— 0/1 slides

— 0/1 slides

100% 1/1 slides

— 0/1 slides

Slide inventory

23

every slide · same image gating as the playbook

01

front_matter

Open slide detail

02

other

Open slide detail

03

summarize

Open slide detail

04

The slide uses a visual association between the three executives and the logos of companies/products they have been associated with.other

Open slide detailBeat · Team

05

The slide uses a timeline-style layout to represent drug development stages.plan_implementation

Open slide detail

06

transition

Open slide detailBeat · ProblemLoop · Cost Of Inaction

07

summarize

Open slide detailBeat · SolutionLoop · Cost Of Inaction

08

Includes a molecular pathway diagram and a Western blot image as evidence.present_solution

Open slide detailBeat · SolutionLoop · Cost Of Inaction

09

The slide demonstrates superior tumor volume reduction by NXP800 compared to standard-of-care Cisplatin in both SKOV-3 and TOV-21G models.show_traction

Open slide detailBeat · SolutionLoop · Cost Of Inaction

10

Includes a patient-derived xenograft (PDX) study workflow diagram and a tumor volume growth curve.show_traction

Open slide detailBeat · SolutionLoop · Cost Of Inaction

11

The chart shows tumor volume reduction over 28 days compared to vehicle control.show_traction

Open slide detailBeat · SolutionLoop · Cost Of Inaction

12

Clinical trial NCT05226507 status update.plan_implementation

Open slide detailBeat · SolutionLoop · Cost Of Inaction

13

transition

Open slide detailBeat · SolutionLoop · Cost Of Inaction

14

summarize

Open slide detailBeat · SolutionLoop · Cost Of Inaction

15

The visualization is a standard kinome tree map used in pharmaceutical research to demonstrate drug selectivity.compare_peers

Open slide detailBeat · SolutionLoop · Cost Of Inaction

16

Uses a structural biology diagram to illustrate mechanism of action.present_solution

Open slide detailBeat · SolutionLoop · Cost Of Inaction

17

Includes a biological pathway diagram, microscopy images, and an IC50 dose-response curve.present_solution

Open slide detailBeat · SolutionLoop · Cost Of Inaction

18

The charts demonstrate efficacy in specific cell lines (KYSE70 and Cal27) with known genetic alterations.show_traction

Open slide detailBeat · SolutionLoop · Cost Of Inaction

19

Includes two distinct experimental setups: cell proliferation assays and mouse tumor growth models.present_solution

Open slide detailBeat · SolutionLoop · Cost Of Inaction

20

Clinical trial identifier NCT05873686 is provided.plan_implementation

Open slide detailBeat · SolutionLoop · Cost Of Inaction

21

summarize

Open slide detailLoop · Cost Of Inaction

22

summarize

Open slide detailLoop · Cost Of Inaction

23

front_matter

Open slide detail